Hernández YA, Torres HO, Carrasco MB, Nasiff HA, Castelo EL, Pérez PL, Fernández VF

Idioma: Español
Referencias bibliográficas: 30
Paginas: 36-45
Archivo PDF: 62.39 Kb.

FRAGMENTO

Los cambios en el estilo de vida se mantienen como la primera línea de tratamiento en los pacientes con prediabetes;1,2 no obstante, como mantener esos cambios conductuales resulta difícil, el empleo de medicamentos que refuercen la posibilidad de la prevención y eviten la evolución a la diabetes, es algo que se ha venido planteando e investigando en los últimos años.2,3

REFERENCIAS (EN ESTE ARTÍCULO)

1. Inzucchi SE, Sherwin RS. The prevention of type 2 diabetes mellitus. Endocrinol Metab Clin N Am. 2005;34(1):199-219.

2. Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care. 2003;26:977-80.

3. Alberti MM, Zimmet P, Shaw J. International Diabets Federation: a consensus on type 2 diabets prevention. Diabetes UK. Diabetic Medicine. May 2007;24:455-9.

4. Nathan DM, Davidson M, DeFronzo R, Heine RJ, Henry RR, Pratley R, Zinman B, American Diabetes Association. Impaired Fasting Glucose and Impaired Glucose Tolerance. Diabetes Care. 2007;30(3):753-9.

5. Rosenstock J. Reflecting on Type 2 Diabetes Prevention: More Questions than Answers. Diabetes, Obesity & Metabolism. 2007;9(1):39-41.

6. Álvarez C, Martínez M, Pérez Unanua, Pallardo LF. Agentes insulinosensibilizadores: biguanidas y tiazolidinedionas. Medicine. 1997;7(64):2991-7.

7. DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin dependent diabetes mellitus. N Engl J Med. 1995;333:541-9.

8. Knowler WC, Barrett-Conner E, Fowler SE, Hammon RF, Lachin JM, Walker EA, et al, and the Diabetes Prevention Program Research Group: reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.

9. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijav V. Indian Diabetes Prevention Programme (IDPP): the Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prervent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49:289-97.

10. Twigg SM, Kamp MC, Davis TM, Neylon EK, Flack JR, Australian Diabetes Society, Australian Diabetes Educators Association. Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. MJA. 2007;186(9):461-5.

11. Sociedad Europea de Cardiología (ESC) y Sociedad Europea para el estudio de la Diabetes (EASD). Guías de práctica clínica sobre diabetes, prediabetes y enfermedades cardiovasculares. Rev Esp Cardiol. 2007;60(5):525-e1-e64.

12. Garber J, Handelsman Y, Einhorn D, Bergman DA, Bloomgarden ZT, Fonseca V, et al. Diagnosis and Management of Prediabetes in the Continuum of Hyperglycemia -When Do the Risks of Diabetes Begin? A Consensus Statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract. 2008;14(7):933-46.

13. Brock B, Smidt K, Ovesen P, Schmitz O, Rungby J. Is metformin therapy for polycystic ovary syndrome safe during pregnancy? Basic Clin Pharmacol Toxicol. 2005;96:410-2.

14. Glueck CJ, Goldenberg N, Sieve L, Wang P. An observational study of reduction of insulin resistance and prevention of development of type 2 diabetes mellitus in women with polycystic ovary syndrome treated with metformin and diet. Metabolism. 2008;57(7):954-60.

15. American Diabetes Association. Standards of medical care in diabetes-2006. Diabetes Care. 2006;29(Suppl. 1):S4-42.

16. W Campbell. Metformin — life begins at 50: A symposium held on the occasion of the 43rd Annual Meeting of the European Association for the Study of Diabetes, Amsterdam, The Netherlands. September 2007.

17. Sartor G, Scherstén B, Carlström S, Melander A, Nordén A, Persson G. Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes. 1980;29:41-9.

18. Riddle MC. Glycemic management of type 2 diabetes: An emerging strategy with oral agents, insulins, and combinations. Endocrinol Metab Clin N Am. 2005;34(1):77-98.

19. Chiasson JL, Josse RG, Hanefeld M, Karasick A, Laakso M, and The STOPNIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet. 2002;359:2072-7.

20. Chiasson JL, Josse RG, Hanefeld M, Karasick A, Laakso M, and The STOPNIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOPNIDDM trial. JAMA. 2003;290:486-94.

21. Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova- Kurktschiev T. Acarbose allows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke. 2004;35:1073-8.

22. Gerstein Hc, Yusuf S, Colman R, Bosh J, Pogue J. Rationale, design and recruitment characteristics of a largue, simple, international trial of diabetes prevention: the DREAM trial. Diabetologia. 2004;47:1519-27.

23. The DREAM (Diabetes Reduction Approaches with ramipril and rosiglitazone Medications) Trial Investigators. Effect of rosiglitazone on the frecuency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet. 2006;368:1096-105.

24. Rosen CJ. Revisiting the rosiglitazone story. Lessons learned. N Eng J Med. 2010;10:1056-60.

25. The NAVIGATOR Study Group. Effect of Nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362(16):1463-76.

26. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003;26:2929-40.

27. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298(2):194-206.

28. Cure P, Pileggi A, Alejandro R. Exenatide and rare adverse events. N England J of Medicine. 2008;358(18):1969-72.

29. Chia CW, Egan JM. Incretin based therapies in type 2 diabetes. J Clin Endocrinol Metab. 2008;93:3703-16.

30. Nathan DM. Finding new treatment for diabetes. How many, how fast how good? N England J Med. 2007;356(5):437-40.